The 2022 AHA/ACC/HFSA Guidelines – Adopting SGLT-2 Inhibitors Across the Spectrum of Heart Failure SGLT-2 Inhibitors as Primary Prevention of Symptomatic HF—Best Practices Amid 2022 Guidelines

The 2022 AHA/ACC/HFSA Guidelines – Adopting SGLT-2 Inhibitors Across the Spectrum of Heart Failure SGLT-2 Inhibitors as Primary Prevention of Symptomatic HF—Best Practices Amid 2022 Guidelines is organized by Projects In Knowledge Inc. (PIK).

Release Date: Mar 24, 2023
Termination Date: Mar 23, 2024

Activity Goal:
The goal of this program is to provide the most current clinical information and practical management strategies for treating heart failure, as seen in clinical practice, in a customized, interactive, and easily digestible on-demand educational program.

Learning Objective(s):
• Summarize the safety and efficacy data supporting guideline recommendations for the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients at risk for heart failure and with pre-heart failure.

Additional details will be posted as soon as information is available.

0.5 MOC | 0.5 IPCE | 0.5 AMA PRA Category 1 Credit™ | 0.5 Contact Hours | 0.1 CEU